Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

IGC reports positive preclinical data on IGC-M3 in Alzheimer’s

IGC Pharma (NYSE: IGC) has announced promising preclinical results of its novel small molecule, IGC-M3, designed to address multiple biological drivers of Alzheimer’s disease. According to IGC, IGC-M3 demonstrated...

August 12, 2025

Developments

Perimeter sees 100% revenue growth in Q2-2025; reduces operating costs by ~30%; adds to leadership team; and creates IAB

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX: PYNKF) announced that it anticipates total revenue for the second quarter of 2025 to be approximately $500,000, representing YoY growth of approximately 100%...

August 11, 2025

Developments

NRx’s NRC-100 receives Fast Track Designation for suicide ideation in depression

NRx Pharmaceuticals (NASDAQ: NRXP) has announced that the FDA has granted NRC-100 Fast Track Designation as a standalone drug for the treatment of suicidal ideation in patients with depression, including bipolar...

August 11, 2025

Developments

FDA approves PharmaTher’s KETARx for surgical pain management

PharmaTher Holdings (QTCQB: PHRRF; CSE: PHRM) has announced that the FDA has approved its ketamine product, KETARx, for use in surgical pain management. According to PharmaTher, the approval positions the company to...

August 11, 2025

Developments

Modular announces next-gen Pivot insulin pump at ADCES

Modular Medicine (NASDAQ: MODD) has announced its participation at the Association of Diabetes Care & Education Specialists (ADCES) Conference, August 8 to 11, 2025, where it will debut a coming soon campaign for...

August 8, 2025

Developments

Orchestra launches FDA-approved study protocol expanding patient eligibility criteria

Orchestra BioMed (NASDAQ: OBIO) has announced the roll out of an FDA-approved protocol update that enables a significant expansion in patient eligibility criteria for enrollment of its BACKBEAT study evaluating AVIM...

August 8, 2025

Developments

IDMC gives Elicio green light to continue study of ELI-002 7P in PDAC

Elicio Therapeutics (NASDAQ: ELTX) has announced that the Independent Data Monitoring Committee (IDMC) has recommended that its Phase 2 AMPLIFY-7P study in mutant KRAS (mKRAS)-driven pancreatic ductal adenocarcinoma...

August 5, 2025

Developments

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to...

August 5, 2025

Developments

Perimeter joins a select group of medtech innovators in the NVIDIA Connect program

In a LinkedIn post today, Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) revealed that it is now a member of the NVIDIA Connect Program. The company joins other medtech innovators that have recently been accepted...

July 30, 2025

Developments

Perimeter CEO significantly adds to holdings

According to a press release issued by Perimeter Medical Imaging AI (TSXV:PINK; OTCQB:PYNKF), it closed the final tranche of a prospectus offering of units of the company, in which its CEO, Adrian Mendes, participated...

July 29, 2025

Developments

Cook Medical’s launch of new iMRI division may help pave the way for wider and faster adoption of innovative procedures, like Profound’s TULSA

Cook Medical, a large family-owned medical device company known for its focus on minimally invasive treatment options, has launched a new Interventional Magnetic Resonance Imaging (iMRI) division, marking a significant...

July 29, 2025

Developments

Cognito presents positive Spectris data at AAIC; highlights Firefly collaboration for biomarker discovery using BNA technology

Closely held Cognito Therapeutics has announced five new poster presentations at the Alzheimer’s Association International Conference (AAIC) 2025, supporting the clinical efficacy and neuroprotective mechanism of its...

July 29, 2025

Developments

VVT Med completes RTO of V.V.T. Med and Exiteam Acquisition

VVT Med (TSXV: DXI.H) (formerly DXI Capital) announced that it has completed its previously announced acquisition of all of the outstanding securities of V.V.T. Med (VVT) and Exiteam Acquisition (EAC), according to the...

July 23, 2025

Developments

USPTO grants Enveric second patent allowance for next-gen mescaline derivatives

Enveric Biosciences (NASDAQ: ENVB) announced that the U.S. Patent and Trademark Office (USPTO) has granted a second Notice of Allowance for novel compounds within its next-generation, non-hallucinogenic mescaline...

July 23, 2025

Developments

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol

Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the critical advancement of its proprietary resveratrol platform, JOTROL, compared to conventional resveratrol formulations, citing breakthrough bioavailability and...

July 23, 2025

Developments

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

Autolus Therapeutics (NASDAQ: AUTL) has announced that the European Commission (EC) has granted marketing authorization for AUCATZYL for the treatment of adult patients aged 26 and over with relapsed or refractory B...

July 21, 2025

Developments

USPTO grants Autonomix patent for smart torquer device

Autonomix Medical (NASDAQ: AMIX) has announced that the United States Patent and Trademark Office (USPTO) has issued a patent for its smart torquer device. The device is designed to enhance the manipulation of elongated...

July 21, 2025

Developments

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license

Cuprina Holdings (NASDAQ: CUPR) has announced the appointment of Dr. Ronald Sherman, a leading innovator in maggot debridement therapy (MDT), as medical and scientific director, effective September 2025—securing the...

July 21, 2025

Developments

Knight files NDS for CREXONT in Canada

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...

July 18, 2025

Developments

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs

Ekso Bionics (NASDAQ: EKSO) has announced the launch of eksoUniversity, a new platform providing continuing education (CE) courses to physical therapists (PTs) and physical therapy assistants (PTAs) across the U.S. Most...

July 18, 2025

Developments

Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC

Cognition Therapeutics (NASDAQ: CGTX) has announced that James Edward Galvin, MD, MPH, will present results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral...

July 17, 2025

Developments

Revelation completes patient dosing in study of Gemini in CKC

Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl...

July 17, 2025

Subscribe